SwissRX Login

Swiss RX login

Connectez-vous pour accéder aux informations destinées aux professionnels: <ul><li>Points forts des publications et des études</li><li>Informations sur les produits et les thérapies</li><li>Services professionnels et matériel à télécharger</li></ul>

Accès pour les professionnels de la santé

Cette page est destinée aux professionels de la santé uniquement

Document introuvable (404)

Par défaut

Vous quittez désormais notre site Internet

Training

Training Title

Cœur et reins

Oncologie

Ophtalmologie

Gynécologie

Radiologie

Domaines thérapeutiques

Pour les patients

ONCOLOGY

Overview

NUBEQA Doublet Combination

NUBEQA Triplet Therapy

Resources for HCPs

Resources for patients

Ordering NUBEQA

Events & Webinars

Publications

Prostate Cancer

Precision Oncology

Bayer Logo

bottom

small_Cardiovascular_32px.png

Cardiovascular

small_Hematology_32px.png

Radiology

Anticoagulation

Chronic Kidney Disease

Hearth Failure

Hematology

small_Oncology_32px.png

Oncology

small_Ophthalmology_32px.png

Ophthalmology

small_Womens_health_32px.png

Women's Health

Short product information NUBEQA®AS.: Darolutamide. I.: NUBEQA is indicated in comb. with androgen deprivation therapy (ADT) for the treatm. of adult pat. with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA is indicated in comb. with docetaxel and ADT for the treatm. of adult pat. with mHSPC, for whom docetaxel therapy is indicated. NUBEQA is indicated in comb. with ADT for the treatm. of adult pat. with non-metastatic, castration-resistant prostate cancer (nmCRPC), for those who are at high risk of develop. metastases (especially with a PSA-DT ≤ 10 m.). D/A: 600 mg (two 300 mg film-coated tablets) taken 2/day with a meal (total daily dose of 1200 mg). pat. receiving NUBEQA should also receive an LHRH agonist or antagonist concurrently or have had a bilat. orchiectomy. When used in comb. with docetaxel, the 1. of 6 docetaxel cycles should begin within 6 weeks of starting NUBEQA. CI.: Hypersensitivity to the active pharmaceut. ingredient or to one of the excipients. Women who are pregnant or of childbearing potential. Spec.W./Prec.: Renal/hepatic impairment: Closely monitor pat. with severe renal impair. or moderate/severe hepatic impair. for adverse reactions. Hepatotox.: In case of liver funct. test abnormalities suggestive of idiosyncr. DILI, NUBEQA must be permanently discont. ADT can prolong the QT interval: In case of risk factors or concomitant medication that prolong the QT interval, ECG monitoring should be consid.. Contraception: Sexually active pat. must use a highly effective form of contracept.. Bone density: may be affected during treatm. with NUBEQA due to long-term testosterone suppr. Recent cardiovasc. disease: The safety of NUBEQA in pat. with a clinic. relevant cardiovasc. disease in the last 6 months has not been proven, follow current guidelines. The prescr. dose is practically “sodium free”. Do not take if you have hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. AEs.: NUBEQA: Very common: Neutrophil count decr., AST and ALT incr., bilirubin incr., fatigue. Common: Ischaemic heart disease, cardiac failure, rash, pain in extremities, fractures. NUBEQA in comb. with docetaxel: Very common: Hypertension including occasional hypertensive emergency, AST incr., ALT incr., bilirubin incr., rash. Interactions: BCRP inhibitor, OATP 1B1 and 1B3, in the case of concurrent use with corresp. substrates, follow the recommendations in the resp. prescrib. information. Weak CYP3A4 inducer. Substrate of CYP3A4, P-gp, and BCRP. Use of strong CYP3A4 inducers and P-gp inducers during treatm. with NUBEQA should be avoided. UE: Very common: Neutrophil count decreased, AST and ALT increased, Bilirubin increased, Fatigue. Common: Ischaemic heart disease, Cardiac failure, Rash, Pain in extremities, Fractures. NUBEQA in combination with Docetaxel: Very common: Hypertension including hypertensive emergency, AST increased, ALT increased, Bilirubin increased, Rash. List: B. Bayer (Schweiz) AG, 8045 Zurich. Further inform.: <a href="https://www.swissmedicinfo-pro.ch/">https://www.swissmedicinfo-pro.ch/</a> RP-M_DAR-CH-0108-4 02/2026 Short product information XOFIGO®Drug substance: Radium Ra-223 dichloride. Indication: Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without known visceral metastases. Anti-androgenic treatment is to be continued to suppress the testosterone levels to castration levels in non-orchiectomized patients. Posology/Administration: 6&nbsp;injections, each of 55&nbsp;kBq per kg body weight, given at 4-week intervals. There is no indication for use in children, adolescents and in women. Xofigo is a therapeutic radiopharmaceutical. Only to be used by authorized personnel with a corresponding license issued by the Federal Office of Public Health. Contraindications: Combination with abiraterone acetate plus prednisone/prednisolone. Pregnancy, women of child-bearing age, during lactation. Special warnings and precautions for use: Adherence to the interval given in the Information for Professionals is recommended for sequential use of abiraterone acetate plus prednisone/prednisolone and Xofigo (or inverse sequence). There are no data on the treatment of patients with asymptomatic bone metastases and is therefore not recommended. Bone marrow suppression, a hematological examination must be carried out before starting treatment and prior to every further dose. Not investigated in patients with Crohn’s disease or ulcerative colitis. In cases of spinal cord compression, standard treatment should be completed in accordance with the clinical indication before starting or resuming treatment with Xofigo. Bone fractures must be treated using orthopedic stabilization before starting or resuming treatment with Xofigo. Potential adverse effects on testicles and sperm, reliable contraception required. Contains sodium. Undesirable effects: Very common: thrombocytopenia, diarrhea, vomiting, nausea. Common: neutropenia, pancytopenia, leukopenia, injection site reactions. Uncommon: lymphopenia Interactions: The safety and efficacy of a combination therapy with Xofigo plus chemotherapy have not been investigated, effects on bone marrow suppression may be additive. Pack sizes: 1&nbsp;vial containing 6&nbsp;mL solution with 6600&nbsp;kBq. Dispensing category A Marketing authorization holder: Bayer (Schweiz) AG, Uetlibergstrasse 132, 8045 Zurich.&nbsp; Detailed Information at <a href="https://www.swissmedicinfo.ch/ShowText.aspx?textType=FI&amp;lang=DE&amp;authNr=62732" target="_blank">www.swissmedicinfo.ch</a>.&nbsp; RP-XOF-CH-0012-2 09/2021

ON Prostate Cancer Resources Patients FR

Resources for your patients

NUBEQA
^®
Doublet (NUBEQA
^®
+ ADT) in mHSPC

Patient guide to treatment with NUBEQA in mHSPC (Doublet) (PDF)

NUBEQA
^®
plus ADT and Docetaxel in mHSPC

Patient guide to treatment with NUBEQA in mHSPC (Triplet) (PDF)

ARASENS – Plain Language Summary in different languages

NUBEQA
^®
plus ADT in nmCRPC

Patient guide to treatment with NUBEQA nmCRPC (PDF)

ARAMIS – Plain Language Summary in different languages

Xofigo® in mCRPC

Patient guide to treatment with XOFIGO (PDF)

Educational material on prostate cancer

INSIGHT PROSTATE App